RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.
Johann Gudjonsson, MD, PhD
Advertisement
Arthur C Curtis Professor of Skin Molecular Immunology, Professor of Dermatology, Professor of Internal Medicine and Research, University of Michigan Medical School
Articles by Johann Gudjonsson, MD, PhD
Johann Gudjonsson, MD, discusses how OX-40/OX-40L signaling drives immune activation in AD and its emerging role as a genetic and therapeutic target.
At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.
Advertisement
Latest Updated Articles
Why the OX-40/OX-40L Pathway Matters in Atopic Dermatitis—and What’s Next: A Q&A with Johann Gudjonsson, MD, PhDPublished: June 12th 2025 | Updated:
Johann Gudjonsson, MD, PhD, on Emerging AD Therapies: From Single Targets to Combination ApproachesPublished: June 19th 2025 | Updated:
- Johann Gudjonsson, MD, PhD: Role of OX-40 Pathway in Atopic Dermatitis Pathogenesis
Published: June 18th 2025 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
Investigational Oral Agent ALZ-801 Slows Brain Atrophy and Cognitive Decline in APOE4 Homozygotes with Early AD
2
Mazdutide Demonstrates Superior Glycemic Control and Weight Loss vs Semaglutide in Head-to-Head Trial
3
Why Do Women Suffer in Silence with Genitourinary Syndrome of Menopause?
4
Chapter 3: neffy (epinephrine nasal spray)
5
